Recent Updates
Recently added Catalysts
KPTI

Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022

Key Takeaway: -- Conference Call Scheduled for Thursday, August 4, 2022, at 8:00 a.m. ET -- NEWTON, Mass., July 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report sec
Price reaction · baseline $69.15 (2022-07-27 close) · hit after-hours · 2 other KPTI headline(s) in the window, move may be shared
day 0 close · peak
-3.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+105%
120-day peak, hindsight
Typical move
15.1%
average across 5 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
Selinexor
Phase 2 · Acute Myeloid Leukemia (AML)

Full Press Release Details

-- Conference Call Scheduled for Thursday, August 4, 2022, at 8:00 a.m. ET --
NEWTON, Mass., July 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 4, 2022, to discuss the financial results and other company updates.
To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
Last updated: Jul 28, 2022